Dyadic International (NASDAQ:DYAI) Stock Crosses Below Fifty Day Moving Average – What’s Next?

Shares of Dyadic International, Inc. (NASDAQ:DYAI) crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.66 and traded as low as $1.52. Dyadic International shares last traded at $1.54, with a volume of 25,519 shares trading hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Dyadic International in a research note on Thursday, November 14th.

Dyadic International Stock Performance

The company has a debt-to-equity ratio of 1.54, a current ratio of 5.15 and a quick ratio of 5.15. The stock has a 50-day moving average price of $1.67 and a 200-day moving average price of $1.39. The company has a market capitalization of $43.50 million, a price-to-earnings ratio of -6.39 and a beta of 0.89.

Dyadic International (NASDAQ:DYAI) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.06. The company had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $1.05 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same quarter last year, the company posted ($0.06) EPS. As a group, analysts forecast that Dyadic International, Inc. will post -0.18 earnings per share for the current year.

Institutional Trading of Dyadic International

A hedge fund recently bought a new stake in Dyadic International stock. Inlet Private Wealth LLC purchased a new stake in Dyadic International, Inc. (NASDAQ:DYAI) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 30,000 shares of the biotechnology company’s stock, valued at approximately $52,000. Inlet Private Wealth LLC owned approximately 0.10% of Dyadic International as of its most recent SEC filing. 27.95% of the stock is owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.